19th September 2011 - New research


Movement Disorders [2011] Sep 12 [Epub ahead of print] (F.Stocchi, R.Borgohain, M.Onofrj, A.H.Schapira, M.Bhatt, V.Lucini, R.Giuliani, R.Anand) Complete abstract

Safinamide is a new type of drug being developed for Parkinson's Disease. Safinamide is believed to have both dopaminergic and non-dopaminergic actions, including the inhibition of monoamine oxidase B (MAO-B) and inhibition of glutamate release. It is intended to be added on to the existing use of L-dopa or dopamine agonists.

In people with early Parkinson's Disease taking a dopamine agonist, the effect of 200mg safinamide was found to be little different from that of a placebo. The effect of 100mg safinamide was found to be significantly better than a placebo. In previous clinical trials, after six months, once daily dosages of 50mg to 100mg Safinamide improved Parkinson's Disease symptoms, and reduced "off" time when added on to the use of existing Parkinson's Disease treatments. However, the reduction in "off" time in comparison to the use of a placebo was minimal. The increase in "on" time beyond that of a placebo was only 40 minutes for 50mg safinamide, and 50 minutes for 100mg safinamide. The side effects of the clinical studies were not disclosed. Higher dosages did not have any beneficial effect. For more current news go to Parkinson's Disease News.

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

















Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports



2006-2011  Viartis
2015-09-06 12:55:51
[email protected]